AERIE PHARMACEUTICALS, INC.

(AERI)
  Report
Delayed Nasdaq  -  04:00 2022-06-24 pm EDT
7.560 USD   +3.28%
06/21AERIE PHARMACEUTICALS, INC.(NASDAQGM : AERI) dropped from S&P Pharmaceuticals Select Industry Index
CI
06/13AERIE PHARMACEUTICALS INC : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
06/08AERIE PHARMACEUTICALS : Corporate Presentation - June 8, 2022
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

AERIE PHARMACEUTICALS INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

05/24/2022 | 07:33am EDT

Item 7.01. Regulation FD Disclosure.

On May 24, 2022, Aerie Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the first patient has been dosed in the Phase 3 registrational study, named COMET-2, to evaluate AR-15512 ophthalmic solution as a treatment for the signs and symptoms of dry eye disease. A copy of this press release is furnished as Exhibit 99.1 hereto and is hereby incorporated by reference into this Item 7.01.

The information in this Item 7.01 (including Exhibit 99.1) is being furnished, not filed, pursuant to Regulation FD. Accordingly, the information in this Item 7.01 will not be incorporated by reference into any registration statement filed by the Company under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference. The furnishing of the information in this Item 7.01 is not intended to, and does not, constitute a determination or admission by the Company that this information is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit relating to Item 7.01 shall be deemed to be furnished, and not filed:

99.1      Press Release Dated May 24, 2022.

104     Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about AERIE PHARMACEUTICALS, INC.
06/21AERIE PHARMACEUTICALS, INC.(NASDAQGM : AERI) dropped from S&P Pharmaceuticals Select Indus..
CI
06/13AERIE PHARMACEUTICALS INC : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
06/08AERIE PHARMACEUTICALS : Corporate Presentation - June 8, 2022
PU
06/08AERIE PHARMACEUTICALS INC : Regulation FD Disclosure, Financial Statements and Exhibits (f..
AQ
05/25AERIE PHARMACEUTICALS TO PARTICIPATE : 30 a.m. ET
BU
05/25AERIE PHARMACEUTICALS : Corporate Presentation - May 25, 2022
PU
05/24Aerie Pharmaceuticals Doses First Participant in Phase 3 Trial of Dry Eye Disease Drug
MT
05/24AERIE PHARMACEUTICALS : Press Release Dated May 24, 2022 - Form 8-K
PU
05/24AERIE PHARMACEUTICALS INC : Regulation FD Disclosure, Financial Statements and Exhibits (f..
AQ
05/24Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational C..
BU
More news
Analyst Recommendations on AERIE PHARMACEUTICALS, INC.
More recommendations